• Explore /
  • Poster
  • / Three-year outcomes of two phase II studies of adjuvant chemotherapy with S-1 plus oxaliplatin or capecitabine plus oxaliplatin in patients with stage III gastric cancer after D2 gastrectomy.

Three-year outcomes of two phase II studies of adjuvant chemotherapy with S-1 plus oxaliplatin or capecitabine plus oxaliplatin in patients with stage III gastric cancer after D2 gastrectomy.

Abstract Poster

Authors

Yoshiaki Nakamura

Yoshiaki Nakamura

National Cancer Center Hospital East, Kashiwa, Japan

Yoshiaki Nakamura , Takeharu Yamanaka , Keisho Chin , Haruhiko Cho , Hitoshi Katai , Masanori Terashima , Seiji Ito , Motohiro Hirao , Kazuhiro Yoshida , Eiji Oki , Mitsuru Sasako , Yasunori Emi , Hideaki Bando , Yoshiyuki Kawashima , Tetsu Fukunaga , Masahiro Gotoh , Takako Ishibashi , Kohei Shitara

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach

Track

Cancers of the Esophagus and Stomach

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

UMIN000026883

Citation

J Clin Oncol 36, 2018 (suppl 4S; abstr 94)

DOI

10.1200/JCO.2018.36.4_suppl.94

Abstract #

94

Poster Bd #

G22

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Gastrointestinal Cancers Symposium

A phase II trial of CapeOX plus nivolumab for early relapsed HER2-negative gastric cancer (JACCRO GC-11: FirSTAR trial).

A phase II trial of CapeOX plus nivolumab for early relapsed HER2-negative gastric cancer (JACCRO GC-11: FirSTAR trial).

First Author: Hiroyuki Arai

First Author: Ilya Tsimafeyeu

First Author: Yu Pengfei

First Author: Zhi Peng